OmicVision Biosciences ApS: Financial statements 2025
CVR: 44285584
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
OmicVision Biosciences ApS (CVR 44285584) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 3,582,426 and a net result of DKK -4,415,945. Equity in the 2025 report amounted to DKK 117,378. The solvency ratio was 1%. The company had 9 employees in the financial year.
- Gross Profit
- DKK 3,582,426
- Profit/Loss
- DKK -4,415,945
- Equity
- DKK 117,378
- Total Assets
- DKK 12,342,387
- Employees
- 9
Official annual report
How creditworthy is OmicVision Biosciences ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
OmicVision Biosciences ApS has published its interim report for the period September 1, 2023 – December 31, 2024.
About OmicVision Biosciences ApS
OmicVision Biosciences ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2023. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Ishani Tara Ummat, Andreas Mund and Maximilian Thomas Dr Strauss. The board consists of Ole Vorm (chair), Andreas Mund and Maximilian Thomas Dr Strauss. The company's owners include VOMA HOLDING A/S, AM Tech Ventures ApS and MS Ventures ApS. The company has 17 employees (2026). In 2025, the company reported a gross profit of DKK 3,582,426 and a net result of DKK -4,415,945. Equity in the 2025 report amounted to DKK 117,378.